comparemela.com

Latest Breaking News On - Source medical - Page 1 : comparemela.com

Real-World Data Show High Discontinuation Rates for Frontline Atezolizumab/Bevacizumab in HCC

Real-world data from a systemic review of treatment patterns in the United States showed that the majority of patients with hepatocellular carcinoma administered atezolizumab and bevacizumab in the frontline setting discontinued treatment within 12 months, indicating the need for additional research on the effectiveness of this regimen for patients with high-risk disease.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.